Fig. 3.

Antiviral activity and clinical impact of HCQ and AZM alone or combined in a Syrian hamster model at 5 dpi.

(a) Experimental timeline (realized on biorender.com). Groups of 6 hamsters were intranasally infected with 1 × 10⁴ TCID₅₀ of SARS-CoV-2, treated from 0 to 3 dpi (blue arrows) and sacrificed at 5 dpi. (b) Lung infectious titers measured using a TCID₅₀ assay. (c–d) Lung viral RNA yields (c) and plasma viral loads (d) measured using a RT-qPCR assay. (e) Clinical follow-up. Animal weights are expressed as normalized weights (i.e. % of initial weight). Data represent mean ± SD of individual data of hamsters (n = 5 to 6; details in Supplemental Table 4)